MAPLE GROVE, Minn. – Upsher-Smith, a subsidiary of Bora Pharmaceuticals, has announced the recent launch of Cyclosporine Ophthalmic Emulsion 0.05%, therapeutically equivalent to the Reference Listed Drug (RLD), RESTASIS (cyclosporine ophthalmic emulsion) 0.05%. According to IQVIA, the cyclosporine ophthalmic emulsion market had U.S. sales of approximately $1.9 billion.
Bora received U.S. Food and Drug Administration (FDA) approval of its abbreviated new drug application (ANDA) for the product in January 2026.
“The launch of cyclosporine ophthalmic emulsion reflects Upsher-Smith’s continued momentum in expanding and diversifying its U.S. portfolio,” said Jim Maahs, Senior Vice President, Head of Upsher-Smith Commercial. “This addition strengthens our ophthalmic offerings and reflects our focus on bringing medicines to market that support the evolving needs of our customers, healthcareproviders and patients.”
Product Information
Product | Strength | NDC # | Package Size |
Cyclosporine Ophthalmic Emulsion | 0.05% | 24979-126-19 | 0.4 mL vials 30-count |
Cyclosporine Ophthalmic Emulsion | 0.05% | 24979-126-18 | 0.4 mL vials 60-count |
These are single-use vials and should be discarded after each use.
For questions about ordering, please call Upsher-Smith at 1-800-654-2299.
